BioInvent International has received further patent protection in China, Japan, and Russia covering the use of BI-505 in cancer patients who have failed to respond…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
BioInvent International has received further patent protection in China, Japan, and Russia covering the use of BI-505 in cancer patients who have failed to respond…
Newly diagnosed multiple myeloma patients who are using statins have lower mortality rates than those who don’t, a large population-based cohort study reported. In the study,…
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an…
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal…
The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…
MYELOMA
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.